Menu
Search
|

Menu

Close
X

CymaBay Therapeutics Inc CBAY.OQ (NASDAQ Stock Exchange Capital Market)

14.98 USD
-- (--)
As of Feb 16
chart
Previous Close 14.98
Open --
Volume --
3m Avg Volume 217,589
Today’s High --
Today’s Low --
52 Week High 15.25
52 Week Low 2.59
Shares Outstanding (mil) 43.86
Market Capitalization (mil) 657.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
5
FY16
0
FY15
0
EPS (USD)
FY17
-0.717
FY16
-1.137
FY15
-0.768
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
137.09
8.57
Price to Book (MRQ)
vs sector
7.59
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
7.87
15.12
LT Debt to Equity (MRQ)
vs sector
4.40
11.85
Return on Investment (TTM)
vs sector
-54.90
13.54
Return on Equity (TTM)
vs sector
-60.93
14.80

EXECUTIVE LEADERSHIP

Robert Wills
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sujal Shah
President, Chief Executive Officer, Since 2017
Salary: $330,000.00
Bonus: $150,000.00
Charles McWherter
Senior Vice President, Chief Scientific Officer, Since
Salary: --
Bonus: --
Daniel Menold
Vice President - Finance, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Kirk Rosemark
Vice President - Regulatory Affairs and Quality Assurance, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7999 Gateway Blvd Ste 130
NEWARK   CA   94560-1188

Phone: +1510.2938800

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

SPONSORED STORIES